The group will start a pilot study at Columbia University next week to sequence genes from 600 Parkinson's disease patients before expanding to a larger cohort.
Fulgent will use its Parkinson's disease NGS panel to target seven genes linked to the condition and generate curated reports for doctors and researchers.
The firm is seeking damages and various injunctions, citing 11 different counts of fraud, breach of contract, tortious interference, and unfair competition.
A new study suggests binding proteins that target glucose or asparagine can be used in combination with cytolysin A-based nanopores to electrically detect the metabolites.
The researchers have built a benchtop breath test currently being validated, but a commercial test could be more than a decade away.
The company hopes to develop saliva-based RNA assays for concussion, Parkinson's disease and autism using biomarkers discovered by its two academic partners.
Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro and said that it plans to assign the assets to a new subsidiary.
The partnership includes biopharmaceutical, life science, and non-profit organizations, as well as several US government agencies.
Investigators concluded that wearables show early promise in some cases, but there's limited evidence to substantiate claims of their ability to improve outcomes.
The partners will use Hummingbird's miRNA database and expertise in sample preparation as well as BGI's BGISEQ sequencer and analysis pipeline to develop targeted miRNA IVD assays.